Previous 10 | Next 10 |
home / stock / smfrw / smfrw news
STAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels. The study demonstrates that using ...
Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child Neurology Society (CNS) Annual Meeting on October 13, 2022 STAMFORD, Conn., ...
STAMFORD, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it is a partner in the recently launched GUARDIAN study (Genomic Uniform-screening Against Rare Diseases In All Newborns), a collaboration among premier non-profit, academ...
NEW YORK, NY / ACCESSWIRE / September 2, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("SMFR" or the "Company") (NASDAQ:SMFR,SMFRW). If you suffered losses exceeding $50,000 investing in Sema4 stock ...
The following slide deck was published by Sema4 Holdings Corp. in conjunction with their 2022 Q2 earnings call. For further details see: Sema4 Holdings Corp. 2022 Q2 - Results - Earnings Call Presentation
New management team implements significant restructuring to focus on profitable growth, efficiency, and scale 19% pro forma 1 volume growth vs. 2Q 2021 Sema4 to host a conference call today at 4:30 p.m. ET STAMFORD, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE)...
Founder Eric Schadt steps down from the organization , including his role as President & Chief R&D Officer Matthew Davis named Chief Technology & Product Officer to further drive t he company’s mission to unlock insights from data, leading to h...
STAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the second quarter of 2022 after the market close on Monday, August 15, 2022. On the same ...
Appoints Richard Miao, Sema4’s Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical ...
The following slide deck was published by Sema4 Holdings Corp. in conjunction with this event. For further details see: Sema4 Holdings (SMFR) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Warrant Company Name:
SMFRW Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...